Spain Infectious Disease Therapeutics Market Report 2022 to 2030

Spain Infectious Disease Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Spain infectious disease therapeutics market will reach a value of $3.01 Bn from $2.31 Bn in 2022, growing at a CAGR of 2.6% during 2022-2030. Infectious Disease Therapeutics in Spain is dominated by a few domestic pharmaceutical companies such as Grifols, AB-Biotics and Zendal. The Infectious Disease Therapeutics market in Spain is segmented into different therapeutic areas and different diseases type. The major factors affecting the Spain infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the lack of healthcare funding for infectious diseases treatment in various of areas of Spain.

ID: IN10ESPH038 CATEGORY: Pharmaceuticals GEOGRAPHY: Spain AUTHOR: Dr. Vishwa Modhia

Buy Now

Spain Infectious Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Spain infectious disease therapeutics market will reach a value of $3.01 Bn from $2.31 Bn in 2022, growing at a CAGR of 2.6% during 2022-2030.

Spain is a high-income developed country located in Southwestern Europe. The coastlines include the Bay of Biscay, the Mediterranean Sea, and the Northern Atlantic Ocean. In terms of medication consumption, the Spanish Agency for Medicines and Health Products (AEMPS) is in charge of tracking the country's drug consumption. According to the most recent AEMPS data, the top ten most consumed pharmaceuticals in Spain in 2020 included numerous drugs used to treat infectious disorders, such as antibiotics and antivirals.

Respiratory disorders are the most common infectious diseases in Spain. Throughout Spain, a broad ongoing transmission of a respiratory ailment caused by the new coronavirus (COVID-19) is occurring; as of December 2022, Spain had reported a total of 13,614,807 COVID-19 cases. Spain's government spends 10.7 % of its GDP on healthcare.

Spain Infectious Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Significant investment has been made in the research and development of infectious disease medicines, particularly in HIV/AIDS, hepatitis C, and tuberculosis. Infectious disease therapeutics research in Spain is actively pursued by the Spanish Ministry of Health, the Spanish National Health System, and numerous research organisations. Spain has steadily increased financial assistance from European institutions. In addition, the manufacturing sector in Spain has recently demonstrated its ability to reinvent itself. These aspects could boost Spain's infectious disease therapeutics market.

Market Restraints

Antibiotic overuse has resulted in the creation of drug-resistant bacteria, making it more difficult to treat infectious infections. This resistance can reduce the efficacy of existing medications and increase the demand for new ones. Spain is heavily exposed to pandemic-vulnerable industries. It features a dual labour market and structural unemployment that is high. These factors may deter new entrants into the Spain infectious disease therapeutics market.

Competitive Landscape

Key Players

Grifols - Grifols is a Spanish biopharmaceutical company that develops and manufactures plasma-derived medicines, including treatments for infectious diseases such as hepatitis B and C, and rabies
Zendal - Zendal is a Spanish biotechnology company that develops and produces vaccines and immunotherapies for infectious diseases
AB-Biotics - AB-Biotics is a Spanish biotechnology company that develops and markets probiotics and prebiotics for the prevention and treatment of infectious diseases, among other conditions
Atrys Health - Atrys Health is a Spanish healthcare technology company that provides diagnostic and treatment services for infectious diseases and cancer

Recent Notable Updates

April 2022: Grifols, a global leader in plasma-derived medicines, has completed the acquisition of 100 % of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, a German company that owns 89.88 % of the ordinary shares and 1.08 % of the preferred shares of Biotest AG, a European healthcare company specialising in innovative haematology and clinical immunology.

Healthcare Policies and Reimbursement Scenarios

The Spanish Agency for Medicines and Medical Devices (AEMPS) regulates infectious illness therapies in Spain. Other regulatory bodies in Spain that may be involved in the regulation of infectious disease therapeutics, in addition to the AEMPS, include the Spanish Agency for Health Protection and Promotion (AESGP), which advises the Spanish government on public health matters, and the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), which provides guidance on the use of new treatments within the healthcare system.

In Spain, the government health system, known as the Sistema Nacional de Salud (SNS), manages the reimbursement of infectious illness treatments. The cost of these therapies is either partially or completely reimbursed, depending on the patient's eligibility and the type of treatment. Treatment must be approved by the Spanish Agency for Medicines and Health Products (Agencia Espaola de Medicamentos y Productos Sanitarios, or AEMPS) before it can be reimbursed. AEMPS assesses new medications and therapies for efficacy, safety, and cost-effectiveness before recommending whether they should be supported by the SNS.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Infectious Disease Therapeutics Segmentation

By Mode of Treatment (Revenue, USD Billion):

Vaccines
Drugs

By Applications (Revenue, USD Billion):

HIV/AIDS
Influenza
Hepatitis
Malaria
Tuberculosis
Others

By Disease Type (Revenue, USD Billion):

Viral Diseases
Bacterial Diseases
Fungal Diseases
Parasitic Diseases
Others

By Target Organism (Revenue, USD Billion):

Antibiotics
Antivirals
Antifungals
Anti-Parasitic
Others

By End User (Revenue, USD Billion):

Hospitals and Clinics
Ambulatory Care Centers
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.